CAMBRIDGE, Mass., Dec. 15, 2017 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering and
developing targeted kinase medicines for patients with genomically
defined diseases, today announced the closing of its previously
announced underwritten public offering of 4,259,259 shares of its
common stock at a public offering price of $81.00 per share, including the exercise in full
by the underwriters of their option to purchase additional shares
of common stock. Blueprint Medicines estimates net proceeds from
the offering will be approximately $325.5
million, after deducting underwriting discounts and
commissions and estimated offering expenses.
Goldman Sachs & Co. LLC, Morgan Stanley and Cowen acted as
joint book-running managers for the offering. Canaccord Genuity
acted as co-manager for the offering.
A registration statement on Form S-3 (File No. 333-216573)
relating to these securities has been previously filed with the
Securities and Exchange Commission (SEC) and has become effective.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
A copy of the final prospectus supplement relating to the
offering has been filed with the Securities and Exchange Commission
and may be obtained from Goldman Sachs & Co. LLC by mail at 200
West Street, New York, New York
10282, Attention: Prospectus Department, by telephone at (866)
471-2526, or by email at prospectus-ny@ny.email.gs.com, from Morgan
Stanley & Co. LLC, Attention: Morgan Stanley Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and from Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY 11717, Attention:
Prospectus Department, by telephone at (631) 274-2806, or by fax at
(631) 254-7140.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted
and potent kinase medicines to improve the lives of patients with
genomically defined diseases. Its approach is rooted in a deep
understanding of the genetic blueprint of cancer and other diseases
driven by the abnormal activation of kinases. Blueprint Medicines
is advancing four programs in clinical development for subsets of
patients with gastrointestinal stromal tumors, hepatocellular
carcinoma, systemic mastocytosis, non-small cell lung cancer,
medullary thyroid cancer and other advanced solid tumors, as well
as multiple programs in research and preclinical development.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the estimated net proceeds from the public offering;
future expectations, plans and prospects for Blueprint Medicines
and the timing of these events; and Blueprint Medicines' strategy,
business plans and focus. The words "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Blueprint Medicines' Quarterly Report on Form 10-Q for the
quarter ended September 30, 2017, as
filed with the SEC on October 31,
2017, the prospectus supplement related to the public
offering and other filings that Blueprint Medicines may make with
the SEC in the future. Any forward-looking statements contained in
this press release represent Blueprint Medicines' views only as of
the date hereof and should not be relied upon as representing its
views as of any subsequent date. Blueprint Medicines explicitly
disclaims any obligation to update any forward-looking
statements.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-of-common-stock-300572150.html
SOURCE Blueprint Medicines Corporation